Alexis Brice – Director, Brain & Spine Institute (ICM), France
Prof. Alexis Brice, director of the French Brain & Spine Institute (Institut du Cerveau et de la Moelle épinière (ICM)), reveals the recipe behind the success of the center since…
Address: 26 Kallang Place #05-17 Singapore 339157,Singapore
Tel: + (65) 6299 5411
Web: http://www.icmpharma.com.sg/
ICM started in Singapore as a trading entity in 1970 under the name of Woods International Pte Ltd, which now becomes the marketing arm of veterinary products in Singapore and Malaysia. It is also their official tendering agency for pharmaceutical products to the public sector in Singapore.
There manufacturing activities started in 1975 for the range of veterinary products under Carrington brand. In the 1980s, they obtained Good Manufacturing Practice (GMP) certification from Ministry of Health (Singapore) for production of human pharmaceuticals. Thier facilities are capable of producing oral preparations, external preparations, creams and ointments.
ICM is now one of the largest local pharmaceutical manufacturers in Singapore. They have expanded into an organisation with over 60 staffs, headed by a group of professionals including pharmacists, quality control and R&D chemists, microbiologist and trained technicians
Their product range includes pharmaceuticals (both ethical and over-the-counter), cosmetics, household products and chemicals for industrial uses. They also do packing of solid dosage forms such as tablets and capsules for their clients.
Prof. Alexis Brice, director of the French Brain & Spine Institute (Institut du Cerveau et de la Moelle épinière (ICM)), reveals the recipe behind the success of the center since…
Victor Manuel Fernández Navarro, CEO at Vicma, explains how strategically important is to have a healthy business model in the distribution industry through sustainable collection period, attractive profit margins and…
Changi Airport Group’s Ching Kiat LIM reflects on a challenging 2020 for the airline industry, Changi’s longstanding excellence in pharmaceutical distribution, and how COVID-19 has pushed a greater embrace of…
Andrew Frye of medtech giant Baxter outlines his management strategy for the diverse APAC region, how growth was achieved in 2020 despite the drop in non-essential hospital visits and treatments…
Singapore – despite its modest USD 1.22 billion domestic market – has long been one of Asia’s leading biopharmaceutical hubs and a magnet for top talent. Multitudes of biopharma and…
Singapore’s Institute of Mental Health offers a comprehensive range of psychiatric, rehabilitative, and psychotherapy services for the country’s population. CEO Associate Professor Daniel Fung discusses their work to transform mental…
Kevin Zou highlights Novartis Oncology’s footprint and priorities in the diverse Asia-Pacific region, the challenges of introducing cutting-edge cell and gene therapies, how the company works with regulators and payers…
Medtech industry veteran Sanjay Prabhakaran outlines the footprint and strategy of women’s health specialist Hologic in the dynamic Asia-Pacific region, how it leveraged its molecular diagnostics expertise to pivot towards…
Novo Nordisk Singapore’s Praful Chakkarwar explains how he leverages his experience in a range of geographies in his current role, how COVID-19 has helped facilitate the affiliate’s digital transformation, the…
Nawal Roy of global digital health platform Holmusk which aims to establish data as a core utility to the treatment of behavioural health disorders explains the challenges of working in…
ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company. CEO Dr Carl Firth reveals why the company has shifted its focus from oncology to autoimmune diseases. He explains why their lead…
As the most important pharma hub in its region, and one of the most important globally, many companies look to launch new products in Singapore first before expanding to other…
Dr Choong May Ling, Mimi, CEO of Singapore’s Health Sciences Authority (HSA), one of the leading regulatory bodies in the Asia-Pacific region, outlines the impact of Singapore’s status as a…
At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech market and, with a CAGR of nine percent, certainly its most dynamic. Chronic underfunding of healthcare systems…
See our Cookie Privacy Policy Here
